[go: up one dir, main page]

ES2140329A1 - Use of maslinic acid as a protease inhibitor for the treatment of the disease caused by acquired immunodeficiency viruses. - Google Patents

Use of maslinic acid as a protease inhibitor for the treatment of the disease caused by acquired immunodeficiency viruses.

Info

Publication number
ES2140329A1
ES2140329A1 ES009702528A ES9702528A ES2140329A1 ES 2140329 A1 ES2140329 A1 ES 2140329A1 ES 009702528 A ES009702528 A ES 009702528A ES 9702528 A ES9702528 A ES 9702528A ES 2140329 A1 ES2140329 A1 ES 2140329A1
Authority
ES
Spain
Prior art keywords
treatment
acquired immunodeficiency
protease inhibitor
maslinic acid
disease caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009702528A
Other languages
Spanish (es)
Other versions
ES2140329B1 (en
Inventor
Granados-Lopez De Hierr Garcia
Rodriguez Antonio Martinez
Sanchez Andres Parra
Garcia Francisco Rivas
Carrillo De Albornoz Ant Osuna
Lazcano M Carmen Mascaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Original Assignee
Universidad de Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada filed Critical Universidad de Granada
Priority to ES9702528A priority Critical patent/ES2140329B1/en
Publication of ES2140329A1 publication Critical patent/ES2140329A1/en
Application granted granted Critical
Publication of ES2140329B1 publication Critical patent/ES2140329B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de ácido maslínico como inhibidor de serín proteasas para el tratamiento de enfermedades causadas por el virus de inmunodeficiencia adquirida. El ácido 2-alfa,3-bestadihidroxi-28-carboxioleaneno (ácido maslínico) se utiliza, sólo o en combinación con otros fármacos, para la obtención de preparados destinados al tratamiento de las enfermedades causadas en humanos y animales por el virus de inmunodeficiencia adquirida.Use of maslinic acid as a serine protease inhibitor for the treatment of diseases caused by the acquired immunodeficiency virus. 2-alpha,3-bestadihydroxy-28-carboxyoleanene acid (maslinic acid) is used, alone or in combination with other drugs, to obtain preparations for the treatment of diseases caused in humans and animals by the acquired immunodeficiency virus .

ES9702528A 1997-12-04 1997-12-04 USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY. Expired - Fee Related ES2140329B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9702528A ES2140329B1 (en) 1997-12-04 1997-12-04 USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9702528A ES2140329B1 (en) 1997-12-04 1997-12-04 USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.

Publications (2)

Publication Number Publication Date
ES2140329A1 true ES2140329A1 (en) 2000-02-16
ES2140329B1 ES2140329B1 (en) 2000-10-16

Family

ID=8301402

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9702528A Expired - Fee Related ES2140329B1 (en) 1997-12-04 1997-12-04 USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.

Country Status (1)

Country Link
ES (1) ES2140329B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003226A1 (en) * 2004-06-30 2006-01-12 Universidad De Granada Use of maslinic acid as a food additive
ES2304322A1 (en) * 2007-03-23 2008-10-01 Universidad De Granada Use of maslinic acid and derivatives thereof for treatment of diseases connected with elastase inhibition, such as neuromas, erythemas, sun and heat burns, and psoriasis
ES2392522A1 (en) * 2011-05-28 2012-12-11 Universidad De La Laguna COMPOSITION FOR MAINTENANCE OF CONTACT LENSES THAT RESULTS EFFECTIVELY AGAINST ACANTHAMOEBA SSP.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008180A1 (en) * 1995-08-30 1997-03-06 University Of Alabama At Birmingham Method to improve the biological and antiviral activity of protease inhibitors
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
WO1997026880A2 (en) * 1996-01-26 1997-07-31 Pharmacia & Upjohn Company Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
US5916919A (en) * 1997-06-27 1999-06-29 Dalhousie University Retrovirus protease inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
WO1997008180A1 (en) * 1995-08-30 1997-03-06 University Of Alabama At Birmingham Method to improve the biological and antiviral activity of protease inhibitors
WO1997026880A2 (en) * 1996-01-26 1997-07-31 Pharmacia & Upjohn Company Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
US5916919A (en) * 1997-06-27 1999-06-29 Dalhousie University Retrovirus protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU H-X et al.: "Anti-HIV triterpene acids from Geum japonicum", 1996, J. Natural Products, 59 (7), paginas 643-645 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003226A1 (en) * 2004-06-30 2006-01-12 Universidad De Granada Use of maslinic acid as a food additive
WO2006003225A1 (en) * 2004-06-30 2006-01-12 Universidad De Granada Use of maslinic acid as an additive in animal production
ES2249153A1 (en) * 2004-06-30 2006-03-16 Universidad De Granada Use of maslinic acid as an additive in animal production
ES2249153B1 (en) * 2004-06-30 2007-02-16 Universidad De Granada MASLINIC ACID AS AN ADDITIVE FOR ANIMAL PRODUCTION.
ES2288357A1 (en) * 2004-06-30 2008-01-01 Universidad De Granada Use of maslinic acid as an additive in animal production
ES2288357B1 (en) * 2004-06-30 2009-03-16 Universidad De Granada MASLINIC ACID AS FOOD ADDITIVE.
ES2304322A1 (en) * 2007-03-23 2008-10-01 Universidad De Granada Use of maslinic acid and derivatives thereof for treatment of diseases connected with elastase inhibition, such as neuromas, erythemas, sun and heat burns, and psoriasis
WO2008116959A1 (en) * 2007-03-23 2008-10-02 Universidad De Granada Use of maslinic acid and derivatives thereof for treatment of diseases connected with elastase inhibition, such as neuromas, erythemas, sun and heat burns, and psoriasis
ES2304322B1 (en) * 2007-03-23 2009-08-13 Universidad De Granada USE OF MASLINIC ACID AND ITS DERIVATIVES FOR THE INHIBITION OF ELASTASA AND FOR THE TREATMENT OF DISEASES AND SYMPTOMATOLOGIES WITH THEM RELATED.
ES2392522A1 (en) * 2011-05-28 2012-12-11 Universidad De La Laguna COMPOSITION FOR MAINTENANCE OF CONTACT LENSES THAT RESULTS EFFECTIVELY AGAINST ACANTHAMOEBA SSP.

Also Published As

Publication number Publication date
ES2140329B1 (en) 2000-10-16

Similar Documents

Publication Publication Date Title
BRPI0411900A (en) antiviral compounds and methods
EA200100524A1 (en) AMIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS MEDICINES
EA199901031A1 (en) Derivatives of benzimidazole
HN1999000124A (en) SUBSTITUTED PYRAZOLE DERIVATIVES.
BR0009964A (en) Artificial peptides with surface activity and their use in the preparation of artificial surfactant
FI20001231A7 (en) 2-Deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives and their analogues and their use as antiviral agents
DE60311272D1 (en) NEW PURINE OR PYRROLOL (2,3-D) PYRIMIDIN-2-CARBOXYLIC ACID FOR THE TREATMENT OF CYSTEIN PROTEASE ACTIVITY ASSOCIATED DISEASES
MX9207334A (en) NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
EA200101155A1 (en) ANTI-TUMOR COMPOUNDS ACTIVATED BY PROTEIN FIBROAST ACTIVATION (FAP)
TR199800818A2 (en) Substituted diaminocarbonic acids.
EE04938B1 (en) Orthosubstituted anthranilic acid amides and their use as medicaments
GT200300244A (en) POSITIONAL ISOMERS OF IFN PEG ALFA 2A
ES2115756T3 (en) SULPHONIC ACID DERIVATIVES USED IN THE TREATMENT OF VIRAL DISEASES.
ATE111735T1 (en) USE OF THE ACTIVE INGREDIENTS AZELASTINE AND GLYCERINE ETHERS TO COMBAT PSORIASIS DISEASES.
WO2004060381A8 (en) Rabbit skin comprising biological active substance and its use
ES2158094T3 (en) ADDITION SALTS OF COMPOUND ACID OF 2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPINA.
ES2140329A1 (en) Use of maslinic acid as a protease inhibitor for the treatment of the disease caused by acquired immunodeficiency viruses.
ES2124861T3 (en) AMINO ACID DERIVATIVES AND THEIR USE AS ENCEPHALINASE INHIBITORS.
MX9403032A (en) QUINOLYL-DIHYDROPYRIDINES, CONDENSED, PROCEDURE FOR ITS MANUFACTURE AND ITS USE IN MEDICINES.
NO954702L (en) Aryl forming drugs
ES2185310T3 (en) HERBAL ANTIVIRICAL AGENT.
ES2169040T3 (en) RESISTANT PLANT TO TWO OR MORE VIRUSES AND PREPARATION OF THE SAME.
ES2131467B1 (en) USE OF MASLINIC ACID AS A SERIN-PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASES CAUSED BY PARASITES OF THE GENE CRYPTOSPORIDIUM.
HN2000000078A (en) AMIDAS REPLACED FENILCICLOHEXANOCARBOXILICO ACID AND ITS USE AS INHIBITORS OF ADENOSINE INCORPORATION
PT100284A (en) BENZIMIDAZOLE ANTI-HELMINTIC FOR USE IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF MICROSPORIDE INFECTION

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000216

Kind code of ref document: A1

Effective date: 20000216

FD2A Announcement of lapse in spain

Effective date: 20180326